荣昌生物预计2026年上半年营收58.5亿元、归母净利47亿元并扭亏为盈

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

# RemeGen Co., Ltd.* 榮 昌 生 物 製 藥 ( 煙 台 ) 股 份 有 限 公 司

(A joint stock company incorporated in the People’s Republic of China with limited liability)

(Stock Code: 9995)

## INSIDE INFORMATION ESTIMATED 2026 INTERIM RESULTS

This announcement is made by RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司(the “Company”) pursuant to the disclosure obligations under Rule 13.09(2)(a) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “Board”) of directors (the “Directors”) of the Company wishes to inform the shareholders and potential investors of the Company that the financial data of the Company for the six months ended June 30, 2026 (the “2026 Interim Period”) contained in this announcement has been prepared in accordance with the China Accounting Standards for Business Enterprises and is only a preliminary estimate on the unaudited accounting data. There may be discrepancies between the data contained herein and the final data to be disclosed in the 2026 Interim Report of the Company. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

#### I. ESTIMATED RESULTS FOR THE PERIOD

- (I) Period for Estimated Results January 1, 2026 – June 30, 2026
- (II) Estimated Results


- (1) According to the preliminary estimate made by the finance department of the Company, the operating revenue for the 2026 Interim Period is estimated to be approximately RMB5,850 million, representing an increase of approximately RMB4,752.05 million in revenue as compared with the same period of last year and a year-on-year increase of approximately 433%.


- (2) The Company estimates that the net profit attributable to owners of the parent company for the 2026 Interim Period will be approximately RMB4,700 million, representing a turnaround as compared with the same period of last year.
- (3) The Company estimates that the net profit attributable to owners of the parent company after deducting the non-recurring gains and losses for the 2026 Interim Period will be approximately RMB4,300 million, representing a turnaround as compared with the same period of last year.


#### (III) The financial figures relating to the estimated results for the 2026 Interim Periodhave not been pre-audited by certified public accountants.

- II. RESULTS FOR THE SAME PERIOD OF LAST YEAR The operating revenue for the same period of last year was RMB1,097.9534 million.

The net loss attributable to owners of the parent company for the same period of last year was RMB449.5687 million.

The net loss attributable to owners of the parent company after deducting the non-recurring gains and losses for the same period of last year was RMB445.5175 million.

- III. MAIN REASONS FOR THE CHANGE IN RESULTS FOR THE PERIOD

During the 2026 Interim Period, the sales revenue from the Company’s core products, telitacicept and disitamab vedotin, has continued to grow in the PRC; meanwhile, the Company has entered into an exclusive licensing agreement with an AbbVie controlled company (hereinafter referred to as “AbbVie”) regarding RC148, pursuant to which AbbVie will obtain the exclusive rights to develop, manufacture, and commercialize RC148 outside the Greater China region, leading to a significant increase in technology licensing revenue, and it is expected to record a profit for the first half of 2026.

- IV. RISK WARNING


As at the date of this announcement, there are no material uncertainties that will affect the accuracy of the estimated results for the 2026 Interim Period.

#### V. OTHER MATTERS

The figures as mentioned above are only based on preliminary estimates. Please refer to the 2026 Interim Report of the Company to be officially disclosed by the Company for accurate financial data. Shareholders and investors are advised to pay attention to the investment risks.

Yantai, The People’s Republic of China August 5, 2026

By order of the Board RemeGen Co., Ltd.* Mr. Wang Weidong

### Chairman and executive Director

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Ms. Fang Michelle Yi and Mr. Wang Yuxiao as the executive Directors, Dr. Wang Liqiang as the non-executive Director, and Mr. Song Xiliang, Mr. Huang Guobin and Mr. Chen Yunjin as the independent non-executive Directors.

### * For identification purpose only